Aoxing Pharmaceutical Company, Inc. reported earnings results for the first quarter ended September 30, 2012. For the quarter, the company reported sales were $2,604,764, representing a 70% increase over the sales realized during the first quarter of the 2012 fiscal year. The increase was primarily attributable to the 78% increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core dental market.

Sales of Zhongtongan accounted for 92% of sales during the quarter ended September 30, 2012. The company recorded a net loss of $448,516 for the first quarter of fiscal 2013, an improvement from the net loss of $955,163 recorded in the first quarter of fiscal 2012.